Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): An analysis from the phase 3 SPARTAN trial.

被引：0
|
作者：
Small, Eric Jay
Saad, Fred
Rathkopf, Dana E.
Hadaschik, Boris A.
Chowdhury, Simon
Yu, Margaret K.
Lopez-Gitlitz, Angela
Rooney, Oliver Brendan
Shu, Youyi
Darif, Mohamed
Smith, Matthew Raymond
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[2] Univ Montreal, Ctr Hosp Univ Montreal CRCHUM, Montreal, PQ, Canada
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Weill Cornell Med Coll, New York, NY USA
[5] Univ Duisburg Essen, Essen, Germany
[6] Guys Kings & St Thomas Hosp, London, England
[7] Janssen Res & Dev, Los Angeles, CA USA
[8] Janssen Res & Dev, High Wycombe, Bucks, England
[9] Janssen Res & Dev, Collegeville, PA USA
[10] Janssen Res & Dev, San Diego, CA USA
[11] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
[12] Harvard Med Sch, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.5034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5034
引用
收藏
页数：2
相关论文
共 50 条
  • [11] SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Small, Eric Jay
    Saad, Fred
    Chowdhury, Simon
    Hadaschik, Boris A.
    Graff, Julie Nicole
    Olmos, David
    Mainwaring, Paul N.
    Uemura, Hiroji
    Lopez-Gitlitz, Angela
    Trudel, Geralyn Carol
    Espina, Byron M.
    Shu, Youyi
    Park, Youn C.
    Rackoff, Wayne R.
    Yu, Margaret K.
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [12] Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Jay Small, Eric
    Saad, Fred
    Chowdhury, Simon
    Oudard, Stephane
    Hadaschik, Boris A.
    Graff, Julie N.
    Olmos, David
    Mainwaring, Paul N.
    Lee, Ji Youl
    Uemura, Hiroji
    De Porre, Peter
    Smith, Andressa
    Doris Brookman-May, Sabine
    Li, Susan
    Zhang, Ke
    Brendan Rooney, Oliver
    Lopez-Gitlitz, Angela
    Raymond Smith, Matthew
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [13] SPARTAN, a phase 3 double-blind, randomized study of apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC)
    Hadaschik, B. A.
    Small, E. J.
    Saad, F.
    Chowdhury, S.
    Graff, J. N.
    Olmos, D.
    Mainwaring, P. N.
    Uemura, H.
    Lopez-Gitlitz, A.
    Trudel, G. C.
    Espina, B. M.
    Shu, Y.
    Park, Y. C.
    Rackoff, W. R.
    Yu, M. K.
    Smith, M. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 43 - 43
  • [14] Efficacy of subsequent treatments in patients who progressed to mCRPC following treatment with apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): A post-hoc analysis of the SPARTAN phase III trial.
    Oudard, Stephane
    Hadaschik, Boris A.
    Antoni, Laurent
    Diels, Joris
    Luccarini, Irene
    Thilakarathne, Pushpike
    Smith, Matthew Raymond
    Small, Eric Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [15] Relationship between apalutamide (APA) exposure and metastasis-free survival (MFS) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN
    Smith, M. R.
    Perez-Ruixo, C.
    Ackaert, O.
    Ouellet, D.
    Chien, C.
    Uemura, H.
    Olmos, D.
    Mainwaring, P. N.
    Lee, J. Y.
    Yu, M. K.
    Perez-Ruixo, J-J.
    Small, E. J.
    ANNALS OF ONCOLOGY, 2018, 29 : 278 - 278
  • [16] Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial.
    Smith, Matthew Raymond
    Fizazi, Karim
    Tammela, Teuvo L. J.
    Cruz, Felipe Melo
    Nordquist, Luke T.
    Aleman Polanco, Diana Sofia
    Emmenegger, Urban
    Silveira, Glauco Costa
    Concepcion, Raoul S.
    Paula, Adriano
    de Mendonca Beato, Carlos Augusto
    Fleshner, Neil
    Richardet, Martin Eduardo
    Kuss, Iris
    Le Berre, Marie-Aude
    Borghesi, Gustavo
    Sarapohja, Toni
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [17] Molecular determinants of prostate specific antigen (PSA) kinetics and clinical response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in SPARTAN.
    Saad, Fred
    Garff, Julie N.
    Hadaschik, Boris A.
    Oudard, Stephane
    Mainwaring, Paul N.
    Bhaumik, Amitabha
    Gormley, Michael
    Lodhe, Anil
    Thomas, Shibu
    Lopez-Gitlitz, Angela
    Mundle, Suneel
    Davicioni, Elai
    Small, Erci Jay
    Smith, Matthew Raymond
    Feng, Fleix Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [18] DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Yu, Evan Y.
    Pieczonka, Christopher Michael
    Armstrong, Andrew J.
    Suzuki, Hiroyoshi
    Bailen, James L.
    Murphy, Declan G.
    Lebret, Thierry
    Luz, Murilo
    Thiery-Vuillemin, Antoine
    Ortiz, Jorge A.
    Khan, Javeed
    Briganti, Alberto
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17029 - E17029
  • [19] Apalutamide and overall survival in patients with nonmetastatic castration-resistant prostate cancer: Updated results from the phase 3 SPARTAN study
    Tan, Thean
    Smith, Matthew R.
    Fred, Saad
    Chowdhury, Simon
    Oudard, Stephane
    Hadaschik, Boris A.
    Graff, Julie N.
    Olmos, David
    Mainwaring, Paul N.
    Lee, Ji Youl
    Uemura, Hiroji
    De Porre, Peter
    Smith, Andressa
    Zhang, Ke
    Lopez-Gitlitz, Angela
    Small, Eric J.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 123 - 123
  • [20] ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Fizazi, Karim
    Shore, Neal D.
    Tammela, Teuvo
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris Y.
    Kuss, Iris
    Kappeler, Christian
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345